Paclitaxel/Pimecrolimus

紫杉醇/吡美莫司

Report date: 2026/03/06 20:02:51

Base Information

Drug NamePaclitaxel/Pimecrolimus
Drug Alias NamePaclitaxel+Pimecrolimus吡美莫司+紫杉醇Pimecrolimus+Paclitaxel紫杉醇+吡美莫司吡美莫司/紫杉醇 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin inhibitorsCalcineurin inhibitorsFK506-binding protein 1A ligand
TargetsTubulinCalcineurinFK506-binding protein 1A
Therapy Area/IndicationsCoronary Artery Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes PimecrolimusPaclitaxel
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgCardinal Health IncJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCardinal Health IncNovartis Pharma AgJohnson & Johnson
Active IndicationsN/A
Inactive IndicationsCoronary Artery Disease

Other Information

ATC CodeN/A
Related LinksN/A